Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per Share

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous estimate of $4.66. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.11. The business had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%.

TVTX has been the topic of a number of other research reports. Wedbush reissued an “outperform” rating and set a $13.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Wells Fargo & Company increased their price objective on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Friday, February 16th. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Finally, Piper Sandler increased their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, January 18th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock opened at $5.45 on Thursday. The company has a market cap of $414.80 million, a P/E ratio of -3.39 and a beta of 0.58. The business has a 50-day moving average price of $7.41 and a two-hundred day moving average price of $7.68. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88. Travere Therapeutics has a 1-year low of $5.25 and a 1-year high of $22.75.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 19,122 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.70, for a total value of $166,361.40. Following the completion of the sale, the chief executive officer now owns 350,600 shares in the company, valued at approximately $3,050,220. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Peter Heerma sold 4,195 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.53, for a total transaction of $35,783.35. Following the completion of the sale, the insider now owns 99,503 shares in the company, valued at approximately $848,760.59. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Eric M. Dube sold 19,122 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.70, for a total transaction of $166,361.40. Following the sale, the chief executive officer now owns 350,600 shares of the company’s stock, valued at approximately $3,050,220. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,773 shares of company stock worth $300,625. Insiders own 3.75% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

Several large investors have recently modified their holdings of TVTX. Avidity Partners Management LP purchased a new stake in shares of Travere Therapeutics during the 3rd quarter worth approximately $11,828,000. Kynam Capital Management LP increased its stake in shares of Travere Therapeutics by 105.6% during the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock worth $17,980,000 after purchasing an additional 1,027,398 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $5,711,000. Finepoint Capital LP increased its stake in shares of Travere Therapeutics by 60.2% during the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock worth $12,904,000 after purchasing an additional 539,500 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Travere Therapeutics by 10.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock worth $41,727,000 after purchasing an additional 460,176 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.